Author

Krissy Kobata

OpenAlex ID: A5028702153

Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program

2021 · Amer M. Zeidan, Aref Al-Kali, et al. · Blood · 12

Stimulus MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very High-Risk Myelodysplastic Syndrome (MDS)

2022 · Amer M. Zeidan, Amy E. DeZern, et al. · Blood · 3

MDS-476 Sabatolimab (MBG453) Combination Treatment Regimens for Patients With Higher-Risk Myelodysplastic Syndromes (HR-MDS): The Myelodysplastic Syndromes Studies in the STIMULUS Immuno-Myeloid Clinical Trial Program

2022 · Amer M. Zeidan, Aref Al-Kali, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

MDS-364: STIMULUS MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very High–Risk Myelodysplastic Syndromes (MDS)

2021 · Amer M. Zeidan, Amy DeZern, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

Poster: MDS-476 Sabatolimab (MBG453) Combination Treatment Regimens for Patients With Higher-Risk Myelodysplastic Syndromes (HR-MDS): The Myelodysplastic Syndromes Studies in the STIMULUS Immuno-Myeloid Clinical Trial Program

2022 · Amer M. Zeidan, Aref Al-Kali, et al. · Clinical Lymphoma Myeloma & Leukemia

Poster: MDS-364: STIMULUS MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very High–Risk Myelodysplastic Syndromes (MDS)

2021 · Amer M. Zeidan, Amy DeZern, et al. · Clinical Lymphoma Myeloma & Leukemia

Works count: 6

Citation count: 17

H-index: 2

I10-index: 1